In the course of our work four (4) patent applications were filed. 1) Electromedical device for intra operative radiation therapy by the means of ionizing radiation with energy higher than 9 MeV. 2) Electron irradiation head position regulation system of electromedical device for intra operative radiation therapy. 3) Electron beam forming system in treatment head of the mobile intra operative accelerator. 4) Electromedical device for intra operative radiation therapy with electronic control of ionization irradiation beam placement. Applications 1-3 have been granted a patent, application 4 is still pending. Conclusions: The IntraLine accelerator meets all of the objectives set for the demonstrator. However, future clinical application of this device may possibly require new mechanical and electrical schemes aiming at minimizing the device's size and weight. Current work also focuses on the device's motion support control system, as well as its treatment planning system.
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EP-1575
First experience with the ArcCHECK QA system J.G. Svestad 1 , H. Lund 1 , B. Saeter 1 , T. Furre 1 , A. Balazs 1 , K. Eklund 1 , Y. Pylypchenko 1 1 DNR -Norwegian Radium Hospital, Department of Medical Physics, Oslo, Norway Purpose/Objective: A 4D detector array (ArcCHECK, Sun Nuclear) has been developed specifically for rotational delivery QA and dosimetry. The purpose of this study was to evaluate the feasibility of the ArcCHECK as a patient specific QA device for different rotational treatment techniques. We report the preliminary results of the evaluation and discuss the determination of clinically relevant acceptance criteria. Materials and Methods: The ArcCHECK device is a cylindrical water-equivalent phantom (PMMA) with a three-dimensional array (21 cm diameter and length) of 1386 diode detectors arranged in a spiral pattern at depth 2.9 cm with 10 mm sensor spacing.. The proprietary SNC Patient software is used to compare the device measured planar dose distribution to that calculated by the TPS. We analyzed 40 treatment plans: 19 Dynamic Conformal Arc Therapy (DCAT) treatment plans for stereotactic radiotherapy of brain tumors, 11 Static Conformal Arc Therapy (SCAT) treatment plans for stereotactic radiotherapy of lung tumors and 10 Volumetric Modulated Arc Therapy (VMAT) treatment plans for different treatment sites (5 lung, 3 head & neck, 1 liver and 1 head). The DCAT plans were constructed and calculated using the iPlan 3.0 TPS while the Oncentra Masterplan 4.3 TPS was used for the other plans. All the patient plans were recalculated for the ArcCHECK phantom geometry. For the DCAT plans a Monte Carlo algorithm was used, while a Collapsed Cone algorithm was used for the SCAT and VMAT plans. All measurements were carried out with 6 MV photon beams on a Varian TrueBeam STx linear accelerator using the ArcCHECK phantom with a solid homogenous PMMA insert. The pass rate of the g index was used to compare the measured and the calculated dose distribution. We used absolute dose mode and local dose difference normalization for the comparison as well as the minimum dose threshold equal to 10%. Two levels of acceptance criteria were tested for the comparison: 3%/3mm and 2%/2mm.
Results:
The measurements performed in the course of approximately 7 weeks showed a stable performance of the ArcCHECK device. Average g-passing rates for all treatment plans, including the passing rate intervals, are shown in Table  1 . Differences in passing rates between the DCAT, SCAT and VMAT plans are all statistically significant (p < 0.05) except between DCAT and SCAT plans using the 3%/3mm criteria.
Conclusions:
In general the ArcCHECK device showed to be a convenient and robust tool for pre-treatment QA which is easy to use and handle. However we found that in order to sharpen the QA acceptance criteria and become more sensitive to the clinically relevant dose differences, it requires tailoring which takes into account beam delivery technique as well as 3D dose distribution. Further work is ongoing to include in the QA routines 3DVH comparison and the possibility to estimate the dose distribution in the patient.
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Comparison of three 2D-array detectors to verify SBRT treatments with the Octavius 4D N. De Marco Blancas 1 , R. García Mollá 1 , J. Bonaque Alandí 1 , L. Vidueira Martínez 1 , M. Guasp Tortajada 1 , N. Montenegro Iglesias 1 1 Consorcio Hospitalario Provincial de Castellón, Servicio de Radiofísica y Protección Radiológica, Castellón de la plana, Spain Purpose/Objective: To compare three 2D-arrays of detectors, which have different distances between detectors and chamber sizes, used to verify SBRT treatments with Octavius 4D. Materials and Methods: Ten SBRT treatments of different locations were selected (including lung, liver, vertebra and nose) for the study. In one of them, four additional plans were made, in three of which the same leaf was shifted a distance of 2, 3 and 4 mm (one distance for each plan) in all beams; in the fourth plan, the leaves positions were randomly changed for overdosing the spinal cord. The intention of the four modified plans was to study the 2Darray sensitivity to detect errors or changes. All treatments were computed by the treatment planning system (TPS) RayStation 4.0.3.4 (RaySearch Laboratories, Stockholm, Sweden) that uses the collapsed cone convolution algorithm. A linear accelerator (Elekta Synergy) was used to verify the SBRT treatments with 6 MV photons. The three 2D-arrays (PTW-Freiburg, Germany) that were used are: Octavius 729 with 729 ionization chambers with dimensions of 5x5x5 mm 3 and a distance of 10 mm between chamber centers, Octavius 1000 SRS with smaller 977 liquid ionization chambers (2.3x2.3x0.5 mm 3 ) and higher resolution (distance of 2.5mm between chamber centers in the central area and 5 mm in the outer area) and Octavius 1500 with 1405 chambers with a size of 4.4x4.4x3 mm 3 and a chamber
